Telehealth companies have rapidly expanded to offer GLP-1 weight loss drugs, capturing a boom in demand. These online platforms provide streamlined access, but researchers and doctors are raising alarms about potential safety risks.
The concern centers on whether virtual providers are adequately screening patients for underlying conditions or monitoring them for side effects. One researcher told KFF Health News that such lapses "give a black eye to telemedicine," highlighting a tension between convenience and patient safety.
Demand for GLP-1 drugs like semaglutide has surged, driving a proliferation of telehealth startups. This growth follows the drugs' proven effectiveness for weight loss, yet oversight has not kept pace, according to those interviewed by KFF Health News.
Regulatory questions loom as more patients access these powerful medications remotely. If online providers fail to uphold traditional care standards, the friction could fuel stricter oversight or harm the reputation of telemedicine broadly.
Experts argue that the industry needs better guardrails to balance accessibility with safety. Without action, the current model risks both patient outcomes and the trust built in virtual care.